Sobre el grupo


Investigador Principal

Antonio Antón Torres 

Equipo

Elena Aguirre Ortega, Vicente Alonso Orduña, Iñaki Alvarez Busto, Angel Artal Cortés, Ana María Comín Orce, Mª Pilar Felices Lobera, Nieves Galán Cerrato, Laura García Clavería, Pablo Gómez Mugarza, Alicia Guerrero Molina, Ibon Gurruchaga Sotés, Ana Herrero Ibañez, Juan Lao Romera, María Belén López Roldan, Diego Márquez Medina, Javier Martínez Trufero, Ana Nuño Alves, Mª Eugenia Ortega Izquierdo, Roberto Antonio Pazo Cid, Teresa Puértolas Hernández, Laura Rodríguez Sastre, María Sánchez Martínez, Carmen Santander Lobera, María Tobeña Puyal, Concepción Velázquez Martínez, Juan Antonio Verdún Aguilar

Hospital Universitario Miguel Servet

Líneas de Investigación


Banco de tumores

Factores pronósticos predictivos de respuesta en diferentes tipos de tumores y situaciones clínicas

Programa de desarrollo y evaluación de nuevos fármacos

Técnicas moleculares de diagnóstico de cáncer familiar y hereditario del síndrome mama / ovario, así como de cáncer colorrectal

Publicaciones más relevantes


Garcia-Foncillas J, Tabernero J, Elez E, Aranda E, Benavides M, Camps C, Jantus-Lewintre E, Lopez R, Muinelo-Romay L, Montagut C, Anton A, Lopez G, Diaz-Rubio E, Rojo F, Vivancos A. Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer. Br. J. Cancer. 2018. 119(12): 1464 - 1470. 10.1038/s41416-018-0293-5.

Balana C, Estival A, Teruel I, Hardy-Werbin M, Sepulveda J, Pineda E, Martinez-Garcia M, Gallego O, Luque R, Gil-Gil M, Mesia C, Del Barco S, Herrero A, Berrocal A, Perez-Segura P, De las Penas R, Marruecos J, Fuentes R, Reynes G, Velarde J, Cardona A, Verger E, Panciroli C, Villa S. Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients. Clin. Transl. Oncol.. 2018. 20(12): 1529 - 1537. 10.1007/s12094-018-1883-7.

Fernandez A, Salgado M, Garcia A, Buxo E, Vera R, Adeva J, Jimenez-Fonseca P, Quintero G, Llorca C, Canabate M, Lopez L, Munoz A, Ramirez P, Gonzalez P, Lopez C, Reboredo M, Gallardo E, Sanchez-Canovas M, Gallego J, Guillen C, Ruiz-Miravet N, Navarro-Perez V, De la Camara J, Ales-Diaz I, Pazo-Cid R, Carmona-Bayonas A. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study. BMC Cancer. 2018. 18(1): 1185 - 1185. 10.1186/s12885-018-5101-3.

Barriuso J, Custodio A, Afonso R, Alonso V, Astudillo A, Capdevila J, Garcia-Carbonero R, Grande E, Jimenez-Fonseca P, Marazuela M, Rodriguez-Antona C, Aller J. Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours. Cancer Treat. Rev.. 2018. 70: 209 - 222. 10.1016/j.ctrv.2018.09.008.

Alemany R, Moura D, Redondo A, Martinez-Trufero J, Calabuig S, Saus C, Obrador-Hevia A, Ramos R, Villar V, Valverde C, Vaz M, Medina J, Felipe-Abrio I, Hindi N, Taron M, Martin-Broto J. Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma. Clin. Cancer Res.. 2018. 24(21): 5239 - 5249. 10.1158/1078-0432.CCR-18-0851.

Diaz-Serrano A, Angulo B, Dominguez C, Pazo-Cid R, Salud A, Jimenez-Fonseca P, Leon A, Galan M, Alsina M, Rivera F, Plaza J, Paz-Ares L, Lopez-Rios F, Gomez-Martin C. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab. Oncologist. 2018. 23(9): 1092 - 1102. 10.1634/theoncologist.2017-0379.

Blancas I, Fontanillas M, Conde V, Lao J, Martinez E, Sotelo M, Jaen A, Bayo J, Carabantes F, Illarramendi J, Gordon M, Cruz J, Garcia-Palomo A, Mendiola C, Perez-Ruiz E, Bofill J, Baena-Canada J, Janez N, Esquerdo G, Ruiz-Borrego M. Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice. Clin. Transl. Oncol.. 2018. 20(7): 862 - 869. 10.1007/s12094-017-1797-9.

Alonso V, Escudero P, Fernandez-Martos C, Salud A, Mendez M, Gallego J, Rodriguez J, Martin-Richard M, Fernandez-Plana J, Manzano H, Mendez J, Zanui M, Falco E, Gil-Raga M, Rojo F, Cuatrecasas M, Feliu J, Garcia-Albeniz X, Maurel J. Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients. Neoplasia. 2018. 20(7): 678 - 686. 10.1016/j.neo.2018.05.004.

del Muro X, Maurel J, Trufero J, Lavernia J, Pousa A, de las Penas R, Cubedo R, Berros J, Herraez A, de Juan A, Broto J. Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study. Invest. New Drugs. 2018. 36(3): 468 - 475. 10.1007/s10637-018-0583-z.

Esteban I, Vilaro M, Adrover E, Angulo A, Carrasco E, Gadea N, Sanchez A, Ocana T, Llort G, Jover R, Cubiella J, Servitja S, Herraiz M, Cid L, Martinez S, Oruezabal-Moreno M, Garau I, Khorrami S, Herreros-de-Tejada A, Morales R, Cano J, Serrano R, Lopez-Ceballos M, Gonzalez-Santiago S, Juan-Fita M, Alonso-Cerezo C, Casas A, Grana B, Teule A, Alba E, Anton A, Guillen-Ponce C, Sanchez-Heras A, Ales-Martinez J, Brunet J, Balaguer F, Balmana J. Psychological impact of multigene cancer panel testing in patients with a clinical suspicion of hereditary cancer across Spain. Psycho-Oncol.. 2018. 27(6): 1530 - 1537. 10.1002/pon.4686.

Gonzalez-Cao M, de las Casas C, Ariza N, Manzano J, Molina-Vila M, Soriano V, Puertolas T, Balada A, Soria A, Majem M, Montagut C, Munoz E, Rodriguez-Abreu D, Perez E, Garcia A, Cortes J, Drozdowskyj A, Karachaliou N, Rosell R, Spanish Melanoma Grp. Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy. Melanoma Res.. 2018. 28(3): 195 - 203. 10.1097/CMR.0000000000000432.

Gravalos C, Carrato A, Tobena M, Rodriguez-Garrote M, Soler G, Vieitez J, Robles L, Valladares-Ayerbes M, Polo E, Limon M, Safont M, de Castro E, Garcia-Alfonso P, Aranda E, Spanish Cooperative Grp Treatment. A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer. Clin. Colorectal Canc.. 2018. 17(2): 323 - 329. 10.1016/j.clcc.2018.02.004.

Lopez R, Herrero C, Khosravi-Shahi P, Porta V, Mena A, Garcia-Foncillas J, Hernandez J, Vilaplana P, Torres A, Diaz-Rubio E, Saus M, Aguilar E. Oncologist's knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study. Clin. Transl. Oncol.. 2018. 20(5): 613 - 618. 10.1007/s12094-017-1756-5.

Nunez-Valdovinos B, Carmona-Bayonas A, Jimenez-Fonseca P, Capdevila J, Castano-Pascual A, Benavent M, Barrio J, Teule A, Alonso V, Custodio A, Marazuela M, Segura A, Beguiristain A, Llanos M, del Prado M, Diaz-Perez J, Castellano D, Sevilla I, Lopez C, Alonso T, Garcia-Carbonero R. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE). Oncologist. 2018. 23(4): 422 - 432. 10.1634/theoncologist.2017-0364.

Gianni L, Mansutti M, Anton A, Calvo L, Bisagni G, Bermejo B, Semiglazov V, Thill M, Chacon J, Chan A, Morales S, Alvarez I, Plazaola A, Zambetti M, Redfern A, Dittrich C, Dent R, Magazzu D, De Fato R, Valagussa P, Tusquets I. Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial A Randomized Phase 3 Clinical Trial. JAMA Oncol.. 2018. 4(3): 302 - 308. 10.1001/jamaoncol.2017.4612.

Abad A, Martinez-Balibrea E, Vieitez J, Alonso-Orduna V, Alfonso P, Manzano J, Massuti B, Benavides M, Carrato A, Zanui M, Gallego J, Gravalos C, Conde V, Provencio M, Valladares-Ayerbes M, Salazar R, Sastre J, Montagut C, Rivera F, Aranda E. Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial. Ann Oncol. 2018. 29(2): 439 - 444. 10.1093/annonc/mdx737.

Martin-Liberal J, Lopez-Pousa A, Martinez-Trufero J, Martin-Broto J, Cubedo R, Lavernia J, Redondo A, Lopez-Martin J, Mulet-Margalef N, Sanjuan X, Tirado O, Garcia-del-Muro X. Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study. Target. Oncol.. 2018. 13(1): 81 - 87. 10.1007/s11523-017-0539-9.

Alsina M, Rivera F, Ramos F, Galan M, Lopez R, Garcia-Alfonso P, Ales-Martinez J, Queralt B, Anton A, Carrato A, Gravalos C, Mendez-Vidal M, Lopez C, de Mena I, Tabernero J, Giralt J, Aranda E, Spanish Cooperative Grp Treatment, GICOR. A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients. Target. Oncol.. 2018. 13(1): 69 - 78. 10.1007/s11523-017-0536-z.

Arriola E, Gomez R, Diz P, Majem M, Aguillo M, Valdivia J, Paredes A, Sanchez-Torres J, Munoz S, Barneto I, Gutierrez V, Santiago J, Aparisi F, Isla D, Ponce S, Baz D, Artal A, Amador M, Provencio M. Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain. BMC Cancer. 2018. 18: 106. 10.1186/s12885-018-4004-7.

Karachaliou N, Gonzalez-Cao M, Crespo G, Drozdowskyj A, Aldeguer E, Gimenez-Capitan A, Teixido C, Molina-Vila M, Viteri S, Gil M, Algarra S, Perez-Ruiz E, Marquez-Rodas I, Rodriguez-Abreu D, Blanco R, Puertolas T, Royo M, Rosell R. Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. Ther. Adv. Med. Oncol.. 2018. 10. 10.1177/1758834017749748.

Otra Actividad